Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Response and Cytokines in Persistent DME
NCT02651168Phase 4Unknown
- Sponsor
- Unity Health Toronto
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Unity Health Toronto. Primary endpoint: Change in aqueous cytokine levels at 3 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02651168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651168.